Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2000

View Archived Issues

ICN acquires three products from Wyeth-Pharma

Role for COX-2 in ischemic damage produced by NO

CRL-1072 enhances antibiotic activity against MAI

Merck describes novel penems with activity against resistant staphylococci

New series of NK2 receptor antagonists developed at Pfizer

Agents for improving insulin resistance designed by AHP scientists

Korean lab focuses on fumagillol derivatives as angiogenesis inhibitors

NC-1175 possesses ATPase-targeted antifungal activity

Centaur continues research into potential new treatments for IBD

Olanzapine and fluoxetine in combination useful for refractory depression

Rat adjuvant arthritis ameliorated by thalidomide analogue

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Sedative/hypnotic neuroactive steroids from CoCensys successfully pass preclinical screening

Abbott's new ketolide ABT-773 will be codeveloped by Taisho

Sumitomo to develop BDNF for new indication: diabetes

Health Canada approves first pill to treat influenza

Depot avorelin produces effective, sustained and safe medical castration in prostate cancer

FDA approves liquid formulation of Celexa for treatment of depression

Isis and Elan to develop antisense drug for HCV

Another major market launch announced for infliximab

BLA submitted for PEG-Intron HCV therapy

PR39 induces therapeutic angiogenesis in preclinical models

Inspire's dry eye product enters phase II testing

BioCryst updates influenza neuraminidase inhibitor program with R.W. Johnson

Qiagen acquires Rapigene

Adult patients with chronic liver disease respond poorly to HBV vaccines

Licensing opportunity from NIH: live attenuated RSV and PIV for use as human vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...